Head to Head: Predictive Oncology vs. CapsoVision

Comparing the business performance and growth potential of two small-cap medical technology companies

Mar. 17, 2026 at 9:54am

Got story updates? Submit your updates here. ›

CapsoVision (NASDAQ:CV) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical technology companies, but which one is the superior business? This analysis compares the two companies across key metrics like revenue, profitability, valuation, and analyst ratings to determine which stock offers more upside potential for investors.

Why it matters

The medical technology sector is highly competitive, with companies vying to develop innovative solutions that can improve patient outcomes and drive revenue growth. Understanding how CapsoVision and Predictive Oncology stack up in terms of financial performance, product pipelines, and market positioning is valuable for investors looking to identify promising investment opportunities in this dynamic industry.

The details

CapsoVision is a commercial-stage company that develops advanced imaging and AI technologies for capsule endoscopy solutions to detect gastrointestinal abnormalities. The company's CapsoCam Plus product is currently its main revenue driver, with plans to expand into colon cancer screening with its CapsoCam Colon pipeline product. Predictive Oncology, on the other hand, operates across four segments - Helomics, zPREDICTA, Soluble, and Skyline - providing a range of cancer research, drug discovery, and medical device services and technologies.

  • CapsoVision began U.S. direct sales of its small-bowel capsule system in 2017.
  • Predictive Oncology was formerly known as Precision Therapeutics Inc. and changed its name in June 2019.

The players

CapsoVision

An American medical technology company that develops advanced imaging and AI technologies for capsule endoscopy solutions.

Predictive Oncology Inc.

A knowledge-driven company focused on developing personalized cancer therapies using artificial intelligence, operating across four business segments.

Got photos? Submit your photos here. ›

The takeaway

While both CapsoVision and Predictive Oncology are small-cap players in the medical technology space, CapsoVision appears to have a more focused, commercially-viable product portfolio and stronger financial performance, making it the more favorable investment option based on the available data.